Therapeutic Strategy Details
| Strategy ID: | S07 |
| Strategy: | Anti-lipogenesis |
| Other Terms: | de novo lipogenesis; de novo lipogenesis; DNL; anti-lipogenic mechanisms; adipogenesis; anti-obesity |
| Related Targets: | stearoyl-CoA desaturase 1 (SCD-1); Acetyl-coenzyme carboxylase; acyl-CoA carboxylase inhibitor (ACC inhibitor); stearoyl Coenzyme A desaturase inhibitor (SCD inhibitor); THR-beta selective agonist; DGAT2 inhibitor; FASN inhibitor |
| Related Drugs: | Aramchol; Firsocostat (GS-0976); VK-2809; ION 224 |
| Mechanism: | Those with NAFLD have increased synthesis of fatty acids. Subjects with NAFLD also had higher nocturnal plasma levels of FFAs and did not suppress the contribution from de novo lipogenesis on fasting. These findings indicate that lipogenesis might be a therapeutic target for NAFLD. Increased de novo lipogenesis is one of the distinguishing features of NAFLD. This indicates that lipogenesis can be a therapeutic target for NAFLD. Proteomic analysis of the Blnc1 ribonucleoprotein complex identified EDF1 as a component of the LXR transcriptional complex that acts in concert with Blnc1 to activate the lipogenic gene program. These findings illustrate a lncRNA transcriptional checkpoint that licenses excess hepatic lipogenesis to exacerbate insulin resistance and NAFLD. |
| Reference (PMIDs): | 16485039; 24316260; 30061575 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D125 | Epanova | Chemical drug | DB11133 | PPARG ligand; PPARA activator | Enhance lipid metabolism | Under clinical trials | Details |
| D137 | Fish oil | Biological drug | DB13961 | -- | -- | Under clinical trials | Details |
| D258 | Omega 3 PUFA | Chemical drug | DB11133 | PPARG ligand; PPARA activator | Hypolipidemic drug | Under clinical trials | Details |
| D383 | Vildagliptin | Chemical drug | DB04876 | DPP4 inhibitor | Antidiabetic drug | Under clinical trials | Details |
| D527 | EPA/DHA | Supplement | DB11133 | -- | -- | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0037 | DB00121 | approved; investigational; nutraceutical | small molecule | Biotin | Target associated | Details |
| R0056 | DB00159 | approved; nutraceutical | small molecule | Icosapent | Therapeutic strategy associated | Details |
| R0594 | DB03796 | approved | small molecule | Palmitic Acid | Target associated | Details |
| R1178 | DB08887 | approved; investigational; nutraceutical | small molecule | Icosapent ethyl | Therapeutic strategy associated | Details |
| R1309 | DB09422 | approved | biotech | Soybean oil | Therapeutic strategy associated | Details |
| R1319 | DB09568 | approved; investigational | small molecule | Omega-3-carboxylic acids | Therapeutic strategy associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00006 | 35256934 | Acta Pharm Sin B | Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. | Details |
| A00030 | 35250593 | Front Pharmacol | Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease. | Details |
| A00056 | 35240344 | Cell Mol Gastroenterol Hepatol | Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis. | Details |
| A00101 | 35219732 | Eur J Pharmacol | mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. | Details |
| A00103 | 35218234 | Hepatology | Dual roles of B lymphocytes in murine models of diet-induced non-alcoholic fatty liver disease. | Details |
| A00110 | 35217259 | J Pharm Biomed Anal | CE with Cu2+ ions and 2-hydroxypropyl-β-cyclodextrin additives for the investigation of amino acids composition of the culture medium in a cellular model of non-alcoholic fatty liver disease. | Details |
| A00188 | 35192934 | Mol Ther | Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma. | Details |
| A00205 | 35187676 | J Food Biochem | Chitosan oligosaccharide attenuates hepatic steatosis in HepG2 cells via the activation of AMP-activated protein kinase. | Details |
| A00256 | 35163881 | Molecules | The Anti-Adiposity Mechanisms of Ampelopsin and Vine Tea Extract in High Fat Diet and Alcohol-Induced Fatty Liver Mouse Models. | Details |
| A00261 | 35162967 | Int J Mol Sci | Quercetin Reduces Lipid Accumulation in a Cell Model of NAFLD by Inhibiting De Novo Fatty Acid Synthesis through the Acetyl-CoA Carboxylase 1/AMPK/PP2A Axis. | Details |
| A00303 | 35144334 | Endocrinol Metab (Seoul) | Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway. | Details |
| A00318 | 35140289 | Sci Rep | Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway. | Details |
| A00331 | 35133139 | Environ Sci Technol | 3-tert-Butyl-4-hydroxyanisole Impairs Hepatic Lipid Metabolism in Male Mice Fed with a High-Fat Diet. | Details |
| A00344 | 35126846 | World J Hepatol | Stearoyl-CoA desaturase 1: A potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence. | Details |
| A00350 | 35124887 | Mol Nutr Food Res | ChREBP-driven DNL and PNPLA3 Expression Induced by Liquid Fructose are Essential in the Production of Fatty Liver and Hypertriglyceridemia in a High-Fat Diet-Fed Rat Model. | Details |
| A00352 | 35124446 | J Pharm Biomed Anal | Targeted metabolomics profiles serum fatty acids by HFD induced non-alcoholic fatty liver in mice based on GC-MS. | Details |
| A00386 | 35107741 | Mol Biol Rep | Alternate-day fasting alleviates high fat diet induced non-alcoholic fatty liver disease through controlling PPARα/Fgf21 signaling. | Details |
| A00400 | 35100965 | Mol Med | Synergistic effects of ISL1 and KDM6B on non-alcoholic fatty liver disease through the regulation of SNAI1. | Details |
| A00519 | 35054478 | Life (Basel) | Deep Sea Water-Dissolved Organic Matter Intake Improves Hyperlipidemia and Inhibits Thrombus Formation and Vascular Inflammation in High-Fat Diet Hamsters. | Details |
| A00538 | 35052685 | Biomedicines | Fatty Acid Synthase Inhibitor Platensimycin Intervenes the Development of Nonalcoholic Fatty Liver Disease in a Mouse Model. | Details |